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OBJECTIVE: Cholinesterase inhibitors have been shown
to delay institutionalization, thus reducing costs. Institu-
tionalization rates, direct, indirect and drug costs were
examined in the Canadian Outcomes Study in Dementia
(COSID); an ongoing observational cohort study of 
clinical and economic outcomes for dementia patients 
in Canada. METHODS: A Cox Proportional Hazards
regression model compared institutionalization rates be-
tween patients receiving (ChI) or not receiving choline-
sterase inhibitors (non-ChI) at the time of enrolment (n =
448). A linear regression model also compared direct out-
patient and inpatient costs (e.g. hospitalisations, commu-
nity services, day surgery), indirect costs (lost caregiver
and patient productivity) and drug costs (including and
excluding ChI costs) in the ChI and non-ChI groups. Both
models adjusted for dementia type, place of residence,
disease duration, baseline Global Deterioration Stage and
Caregiver Burden (ZBI), age and gender. Follow-up was
from baseline to last visit date (between 6 and 18
months). RESULTS: This model-based assessment shows
strong evidence that treatment with ChIs is associated
with reduced institutionalization risk (RR = 0.262, p =
.0032). Because most patients were lost to follow-up on
or shortly after institutionalization, this analysis does not
account for the cost of institutionalization. However,
reducing the rate of institutionalization almost certainly
yields signiﬁcant cost savings. Other signiﬁcant predictors
of risk include baseline ZBI (RR = 1.033 per point, p =
.0394) and age (RR = 1.107 per year, p = .0085). The
linear regression model for costs demonstrated no signif-
icant differences in inpatient (excluding institutionaliza-
tion), indirect and overall costs between non-ChI and ChI
patients. Drug costs were estimated to be $134 per month
greater for the ChI group than the non-ChI group ($168
vs $34, p < .0001). CONCLUSIONS: The use of ChIs
appeared to have a signiﬁcant effect on institutionaliza-
tion rates and drug costs, but not on other cost drivers in
this disease. The reduced rate of institutionalization likely
translates into cost savings for the ChI treatment strategy.
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OBJECTIVE: To assess the development of costs for
dementia in Germany until 2050 under different demo-
graphic scenarios and the possible impact of treatment
interventions with acethylcholinesterase inhibitors from
various perspectives. METHODS: A model to estimate
cost differences in dementia treatment with acethyl-
cholinesterase inhibitors compared to a placebo scenario
was developed. The model projects the number of demen-
tia patients in Germany until 2050 under the assumption
of extended life expectancy and immigration. Markov
modeling allows documenting the progression of demen-
tia patients into more severe disease stages. Data of 
the population development are supplied by the Federal
Bureau of Statistics and the German Institute for Eco-
nomic Research. Number of patients are calculated from
demographic prognoses considering prevalence of disease
data from a published metaanalyses of the epidemiology
of dementia. Data about transition probabilities between
different disease stages are derived from a randomized
clinical trial of an acethycholinesterase drug. Disease
stage speciﬁc costs are taken from a cost of illness study
previously published. RESULTS: The number of demen-
tia patients will increase from 1 million to 2.5 million
over the next 50 years in Germany. With treatment, there
will be 30% less patients in the most severe, and hence
most costly disease stage. Costs for treatment are offset
by cost savings through a shift of patients to less severe
disease stages, if indirect family and caring costs are con-
sidered. Reduction of direct costs due to treatment
increase from €0.5 to €1.5 billion and indirect cost reduc-
tions are fourfold these ﬁgures. For 2000, net savings of
€1.4 billion are demonstrated for the societal perspective.
Results are stable for extensive sensitivity analysis. CON-
CLUSION: Results document that dementia treatment is
economically attractive in an aging society.
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